Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

AL102-502

14 evidence topics · 3 sources

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-502”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-02-24”
Primary completion (actual)“2025-04-08”
Study completion (actual)“2025-05-06”
First posted“2025-03-03”
Last update posted“2025-09-24”
Site“Celerion”; “Tempe”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using placebo-corrected QTc change as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“32”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
  • The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
  • Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.